Bright 1 Bodies Weight Management Program (B1B)

May 29, 2018 updated by: Yale University

Bright 1 Bodies: Extending the Bright Bodies Weight Management Program to Adolescents With Type 1 Diabetes

Physical inactivity occurs among 65% to 95% of youth with type 1 diabetes (T1D) and based upon limited evidence may contribute to the rapidly growing incidence of overweight among this population. The purpose of the present study is to pilot test a 12-week intensive lifestyle program for adolescents with overweight and T1D utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education to address problem solving behaviors that limit their physical activity and weight control. Our primary aim is to evaluate the changes in physical activity adherence, anthropometrics, and self-management behaviors following this program among sedentary adolescents with T1D and overweight (n=25, OW) compared with sedentary adolescents with T1D and normal weight (n=25, NW). We hypothesize that the OW group will achieve improve physical activity adherence and anthropometrics to the same or greater extent as the NW group and previous Bright Bodies cohorts, and that these changes will correlate with improved exercise-related problem solving. Our secondary aim is to evaluate changes in adipocytokines and epigenetic factors related to the etiology of overweight/obesity following our physical activity intervention. We hypothesize changes in these biomarkers will correlate with changes in anthropometry variables and partially explain any differences in response between the groups and individuals should those occur.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Prevalence of overweight among patients with type 1 diabetes (T1D) of all ages has grown at alarming rates since the 1980s. Physical inactivity occurs among 65% to 95% of youth with T1D and doubles their risk of overweight. A major factor limiting their physical activity appears to be self-managed problem solving around exercise such as adjustments to insulin and diet, which is practiced regularly by less than half of our adolescent patients with T1D and less frequently than any other self-management behavior. Our previous interventions applying coping skills training (ABCs of Diabetes and TeenCope) as well as diabetes self-management (Managing Diabetes) successfully improved problem-solving and other aspects of self-management along with health outcomes among adolescents with T1D, but did not focus on those who were overweight nor promotion of physical activity and weight loss. The Yale Bright Bodies intensive lifestyle program successfully promotes physical activity and weight loss, enrolling >100 overweight youth from greater New Haven annually but does not presently accommodate those with T1D.

The purpose of the present study is to pilot test a 12-week intensive lifestyle program for adolescents with overweight and T1D utilizing group exercise classes from Bright Bodies adapted for this population, supplemented with coping skills training and diabetes self-management education to address problem solving behaviors that limit their physical activity and weight control. Our primary aim is to evaluate the changes in physical activity adherence, anthropometrics (body mass index percentile for age, body fat percentage), and self-management behaviors following this 12-week lifestyles program among sedentary adolescents with T1D and overweight (n=25, OW) compared with sedentary adolescents with T1D and normal weight (n=25, NW). We hypothesize that the OW group will achieve improve physical activity adherence and anthropometrics to the same or greater extent as the NW group and previous Bright Bodies cohorts, and that these changes will correlate with improved exercise-related problem solving.

Although physical activity is recommended for weight loss, outcomes from increased physical activity have been heterogeneously distributed-not all overweight participants lose weight and some even gain weight. Furthermore the etiologies of overweight/obesity and T1D appear to interact, yet no study has tested the influence of physical activity upon biological pathways related to overweight/obesity for patients with T1D. Accordingly, our secondary aim is to evaluate changes in adipocytokines and epigenetic factors related to the etiology of overweight/obesity following our physical activity intervention. We hypothesize changes in these biomarkers will correlate with changes in anthropometry variables and partially explain any differences in response between the groups and individuals should those occur.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Connecticut
      • New Haven, Connecticut, United States, 06511
        • Yale Children's Diabetes Program

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years to 19 years (ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient of the Yale-New Haven Hospital (YNHH) Pediatrics Long Wharf or Trumbull Diabetes Clinic
  • Diagnosed with T1D
  • 11 to 19 years old
  • Sedentary (exercise less than twice per week over past two months)
  • n=25 overweight (BMI > 85th percentile for age and sex according to Centers for Disease Control Growth Charts) and n=25 normal weight
  • Family willing to commit the time and effort to a family-based lifestyle program.

Exclusion Criteria:

  • Endocrinopathies other than type 1 diabetes; adequately treated hypothyroidism, as demonstrated by normal thyroid tests within previous six months, is allowed.
  • Concurrent use of systemic (oral, parenteral) glucocorticoids or other medications known to contribute to obesity; inhaled steroids are allowed.
  • Any use of pharmacological intervention for weight management, including prescription medication, over the counter medication, or herbal supplements.
  • Chronic disease or physical disability that would influence treatment intervention or preclude participation in regular physical activity (e.g., chronic renal failure).
  • Psychological conditions such as uncontrolled eating disorder, psychosis, personality disorders and other disorders that will interfere with the ability to maintain complete follow up and adherence to protocol.
  • Any concurrent membership in a comprehensive weight management program.
  • Inability or unwillingness of the parent to accompany the child to nutrition classes.
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: NON_RANDOMIZED
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Overweight
Sedentary adolescents with T1D and overweight
A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
EXPERIMENTAL: Normal Weight
Sedentary adolescents with T1D and normal weight
A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from baseline body mass index (BMI) over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline in daily physical activity energy expenditure over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Change from baseline in Progressive Aerobic Cardiovascular Endurance Run score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline in blood pressure over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline daily insulin usage over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline lipid profile over 12 weeks
Time Frame: Baseline, 12 weeks
Baseline, 12 weeks
Change from baseline adipocytokines over 12 weeks
Time Frame: Baseline, 12 weeks
Baseline, 12 weeks
Change from baseline inflammatory factors including C-reactive protein, interleukin-6, fibrinogen, and plasminogen activator inhibitor-1 over 12 weeks
Time Frame: Baseline, 12 weeks
Baseline, 12 weeks
Change from baseline micro RNA expression over 12 weeks
Time Frame: Baseline, 12 weeks
Baseline, 12 weeks
Change from baseline pediatric quality of life questionnaire score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline diabetes self-care inventory score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline hypoglycemia fear survey score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline psychosocial determinants of physical activity behavior questionnaire score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline self-perception profile for adolescents questionnaire social acceptance subscale score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline in handgrip strength over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline in sit-and-reach test over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks
Change from baseline in push-up test over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
Baseline, 12 weeks, 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Garrett I Ash, PhD, CSCS, Yale University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2016

Primary Completion (ACTUAL)

October 31, 2017

Study Completion (ACTUAL)

November 8, 2017

Study Registration Dates

First Submitted

May 4, 2016

First Submitted That Met QC Criteria

May 9, 2016

First Posted (ESTIMATE)

May 11, 2016

Study Record Updates

Last Update Posted (ACTUAL)

May 30, 2018

Last Update Submitted That Met QC Criteria

May 29, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 1

Clinical Trials on Bright 1 Bodies

3
Subscribe